SION-719 Added to Trikafta for Cystic Fibrosis

SION-719 Added to Trikafta for Cystic Fibrosis
37%21%5%May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 28May 27 • YES 32.1%May 28 • YES 10.6%
Sionna Therapeutics Inc. ($SION)
No stock close$44.35$40.56$36.76May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 28May 18 • SION $39.24May 19 • SION $37.68May 20 • SION $39.50May 21 • SION $41.75May 22 • SION $41.13May 26 • SION $42.88May 27 • SION $43.43May 28 • SION $42.80

Will this trial show a positive result on change from baseline in sweat chloride levels?

Paper Trading
Create account to trade
ClinicalNewsTrialPositionsReasoningOracle
Scientific editorial illustration for Cystic Fibrosis

Cystic Fibrosis

Cystic fibrosis is an inherited disease that makes thick, sticky mucus build up in the lungs and digestive organs. Tracking side effects matters because added treatment should be tolerable while aiming to help people breathe easier.

1U.S. prevalence: About 35,000 people2Global diagnosed population: About 105,000 people3U.S. predicted median survival: 65.4 years